CVC plans to initiate a public delisting tender offer for CompuGroup Medical SE & Co. KGaA at EUR22.00 per share in cash. This price matches the previous takeover offer by CVC, which was completed on May 2, 2025, following its announcement in December 2024.
The managing directors, supervisory board, and administrative board of CompuGroup Medical have expressed their support for this tender offer. They believe it offers shareholders a chance to sell their shares at an attractive price before the company exits the stock exchange, allowing CGM to concentrate more on its long-term innovation and growth strategy.
The delisting tender offer is expected to be announced in May 2025, with an acceptance period also starting that month. The process is anticipated to conclude within the first half of the 2025 financial year and definitely before CGM’s annual general meeting scheduled for August 1, 2025.
CompuGroup Medical SE & Co. KGaA is recognized as a leading e-health company globally, with revenues reaching EUR1.15 billion in 2025. It employs over 8,700 people across locations in 19 countries and markets its products in 60 countries worldwide.
CVC is a prominent global private markets manager operating from 30 offices across EMEA, the Americas, and Asia. It manages approximately EUR200 billion in assets under management with investments in around 140 companies worldwide that generate combined annual sales exceeding EUR168 billion and employ more than 600,000 individuals.
The legal team from A&O Shearman advising on this transaction was led by partner Dr. Christian Eichner and senior associate Eva Hohmann, along with counsel Kyrill Chilevych and associates Dr. Christina Vossen and Lasse Ostholt from Düsseldorf.
Previously, an A&O Shearman team led by Dr. Christian Eichner and Eva Hohmann had advised CompuGroup Medical’s supervisory board regarding CVC’s prior public takeover offer.
